---

---

tags : Phase 2    symbols : Rdhl   

save search

---

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -76.51% | O: 6.63% H: 12.99% C: 6.78%
rhb-107 covid-19 funding study phase 2

---

RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -93.05% | O: 15.68% H: 26.31% C: 9.06%
rhb-107 covid-19 positive results publication study phase 2

---

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2022-03-01 (Crawled : 14:30) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -82.19% | O: 0.46% H: 0.45% C: -10.45%
rhb-107 covid-19 phase 2 covid positive

---

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
Published: 2022-01-13 (Crawled : 18:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -84.02% | O: 0.82% H: 6.1% C: -2.44%
covid-19 phase 2 biopharma clearance phase 2/3 opaganib covid

---

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -92.11% | O: -2.83% H: 0.0% C: 0.0%
covid phase 2 biopharma ongoing phase 2/3

---

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -91.08% | O: 22.54% H: 0.66% C: -8.87%
covid phase 2 biopharma phase 2/3 opaganib

---

RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
Published: 2021-09-14 (Crawled : 12:15) - prnewswire.com
RDHL | $0.425 1.0% 150K |

Health Technology

| -94.72% | O: -32.93% H: 7.07% C: 0.4%
covid phase 2 biopharma phase 2/3 opaganib topline

---

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -95.17% | O: -0.74% H: 0.45% C: -7.98%
covid phase 2 biopharma ongoing phase 2/3 approval

---

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -93.39% | O: 2.37% H: 7.45% C: 3.64%
covid phase 2 biopharma phase 2/3 opaganib covid-19

---

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -94.4% | O: 0.43% H: 1.57% C: -1.14%
covid presentation phase 2 biopharma positive opaganib covid-19

---

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -94.48% | O: 0.57% H: 4.78% C: 3.38%
covid phase 2 biopharma phase 2/3 opaganib enroll covid-19

---

RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Published: 2021-04-09 (Crawled : 12:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -94.19% | O: -0.6% H: 10.79% C: 9.6%
covid phase 2 biopharma phase 2/3 opaganib

---

RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
Published: 2021-02-23 (Crawled : 12:11) - prnewswire.com
RDHL | $0.425 1.0% 150K |

Health Technology

| -96.55% | O: -6.29% H: 2.74% C: -7.47%
covid phase 2 biopharma expansion phase 2/3 opaganib

---

RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
Published: 2021-01-11 (Crawled : 14:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -95.36% | O: -1.9% H: 6.43% C: 5.7%
phase 2

---

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Published: 2020-12-31 (Crawled : 15:07) - prnewswire.com
RDHL | $0.425 1.0% 150K |

Health Technology

| -95.44% | O: 0.93% H: 7.87% C: -6.48%
covid positive biopharma topline phase 2 opaganib

---

RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Published: 2020-12-22 (Crawled : 15:00) - biospace.com/
RDHL | $0.425 1.0% 150K |

Health Technology

| -95.67% | O: 0.55% H: 2.43% C: -0.44%
covid phase 2 opaganib phase 2/3

---

Gainers vs Losers

74%

26%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M |

Finance

EGOX | $0.054 50.0% 290M |

NVFY | $2.71 28.44% 31M |

Consumer Durables

ZCMD | $1.86 28.28% 29M |

Commercial Services

BSFC | $0.0822 27.64% 75M |

Manufacturing

RWOD | $10.08 26.05% 5.6M |

n/a

INDO | $5.1 25.0% 15M |

Energy Minerals

CHRO | $1.53 24.9% 100K |

n/a

INSG | $2.98 23.14% 190K |

Electronic Technology

TPET | $0.4001 22.02% 35M |

n/a

---

Your saved searches

---